论文部分内容阅读
目的研究不同残留剂量恩诺沙星对连续培养系统中肠道菌群数量的影响。方法建立4套连续培养系统,接种正常人粪便于发酵罐中,连续培养肠道菌群23 d;第23天发酵罐中分别泵入含恩诺沙星剂量为0、1.25、12.5和125 mg/L的培养基,连续加药7 d,第31天停止加药。加药前10 d和加药过程中每隔2 d从4个发酵罐中取样并进行活菌计数。结果活菌计数结果表明,空白组菌群数量稳定,说明4套连续培养系统运行稳定;低剂量组(1.25 mg/L)恩诺沙星使双歧杆菌下降3个数量级,对其他菌基本无影响;中剂量组(12.5 mg/L)中除拟杆菌外数量均有所下降,厌氧总菌、乳酸菌和肠杆菌停药前数量恢复到加药前水平,需氧总菌、双歧杆菌和肠球菌数量下降后不能恢复原初水平;高剂量组(125 mg/L)中所计数细菌数量均发生变化,需氧总菌、乳酸菌、双歧杆菌、肠球菌和拟杆菌数量下降且停药前不能恢复原初水平,厌氧总菌和肠杆菌数量先降后升,最终计数结果比加药前数量增加。结论中国现行规定恩诺沙星的日允许摄入量(ADI)可能对人体肠道菌群造成影响。
Objective To study the effects of different residual dose of enrofloxacin on the number of intestinal microflora in continuous culture system. Methods Four continuous culture systems were established and inoculated with normal human excrement in a fermentor for continuous culture of intestinal flora for 23 days. On day 23, fermenters were enrolled in enfloxacin containing enrofloxacin doses of 0, 1.25, 12.5 and 125 mg / L medium, continuous dosing 7 d, the first 31 days to stop dosing. Samples were taken from 4 fermenters and viable bacteria counts were taken every 10 days before dosing and during dosing. Results The count of viable cells showed that the number of bacteria in the blank group was stable, which indicated that the four continuous culture systems were stable. Enrofloxacin of low dose group (1.25 mg / L) decreased Bifidobacterium by three orders of magnitude, (12.5 mg / L) except for Bacteroidetes. The numbers of anaerobic bacteria, lactic acid bacteria and Enterobacter were restored to the level before dosing, the total aerobic bacteria, Bifidobacterium And the number of Enterococcus can not be restored after the decline of the original level; high dose group (125 mg / L) in the number of bacteria were counted changes in aerobic bacteria, lactic acid bacteria, bifidobacteria, enterococci and Bacteroides decreased the number and withdrawal Before the original level can not be restored, the number of anaerobic bacteria and enterobacteria drop first and then increase, the final count results increase than the number before dosing. Conclusion The current allowable daily intake (ADI) of enrofloxacin in China may affect the human intestinal microflora.